SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2008 / Cilt: 18 - Sayı: 4

Kanserli Türk çocuklarında glutatyon S-transferaz, CYP2C9 ve CYP2C19 polimorfizmleri

Glutathione S-transferases CYP2C9 and CYP2C19 polymorphisms in Turkish children with cancer

Öznur DÜZOVALI
Lülüfer TAMER
Nurcan A. ATEŞ
Zekeriya BÜYÜKDERELİ
Hatice YILDIRIM
BAHAR TAŞDELEN
Esat YILGÖR
Uğur ATİK
Pages
201–207
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, GSTM1, GSTP1, and CYP2C9 polymorphisms may play a role in the development of childhood cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We investigated the associations between GSTM1, GSTT1, GSTP1, CYP2C9, CYP2C19 polymorphisms and childhood cancer.
📊
Key Findings & Data:Genotypes were analyzed with real-time PCR in 61 children with cancer and 157 healthy controls.
💡
Conclusion & Impact:In conclusion, GSTM1, GSTP1, and CYP2C9 polymorphisms may play a role in the development of childhood cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Polimeraz zincir reaksiyonu · Sitokrom P-450 enzim sistemi · Çocuk

Abstract

We investigated the associations between GSTM1, GSTT1, GSTP1, CYP2C9, CYP2C19 polymorphisms and childhood cancer. Genotypes were analyzed with real-time PCR in 61 children with cancer and 157 healthy controls. Twenty nine of 61 patients were diagnosed of leukemia and 8 of lymphoma. The remaining patients had solid tumors. GSTM1 null genotype was associated with an increased risk of leukemia and lymphoma (OR= 2.2, 95%CI= 1.1-4.6) (p= 0.03). Presence of at least one mutant allele of GSTP1 was related to an increased risk of solid tumor (OR= 3.3, 95%CI= 1.3-8.3) (p= 0.02). Moreover, CYP2C9*2 allele was a high risk for leukemia and lymphoma (p= 0.04). In conclusion, GSTM1, GSTP1, and CYP2C9 polymorphisms may play a role in the development of childhood cancer.

Özet

Bu çalışmada GSTM1, GSTT1, GSTP1, CYP2C9, CYP2C19 polimorfizmleri ve çocukluk çağı kanserleri arasındaki ilişkinin araştırılması amaçlanmıştır. Kanserli 61 ve sağlıklı 157 çocukta real-time PCR yöntemi kullanılarak genotipler çalışılmıştır. Yirmi yedi hasta lösemi, 8 hasta lenfoma, diğer hastalar solid tümör tanısıyla izlenmekteydi. GSTM1 null genotipi, artmış lösemi/lenfoma gelişme riski ile ilişkiliydi (OR= 2.2, %95CI= 1.1-4.6) (p= 0.03). GSTP1’de en az bir mutant allel varlığı solid tümör görülmesiyle bağlantılı bulundu (OR=3 .3, %95CI=1 .3-8.3) (p= 0.02). CYP2C9*2 alleli taşıma ile lösemi/lenfoma gelişme riski arasında ilişki saptandı (p= 0.04). Sonuç olarak, GSTM1, GSTP1 ve CYP2C9 polimorfizmleri çocukluk çağı kanserlerinin gelişmesinde rol oynayabilirler.

🔖

Cite This Article

DÜZOVALI, Ö., TAMER, L., ATEŞ, N. A., BÜYÜKDERELİ, Z., YILDIRIM, H., TAŞDELEN, B., YILGÖR, E., ATİK, U. (2008). Kanserli Türk çocuklarında glutatyon S-transferaz, CYP2C9 ve CYP2C19 polimorfizmleri. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 18 - Sayı: 4, 201–207. https://ajindex.com/articles/323062

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Perera FP. Molecular epidemiology: Insight into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst 88: 496-509, 1996
  2. Taningher M, Malacarne D, Izzotti A, et al. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutation Res 436: 227-261, 1999
  3. Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 17: 27-41, 2003
  4. Schoket B, Papp G, Levay K, et al. Impact of metabolic genotypes on levels of biomarkers of genotoxic exposure. Mutation Research 482: 57-69, 2001
  5. Goldstein J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52: 349-355, 2001
  6. Roddam PL, Rollinson S, Kane E, et al. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics 10:605-615, 2000
  7. Shi WX, Chen SQ. Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World J Gastroenterol 10: 1961-1963, 2004
  8. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30: 445-460, 1995
  9. Krajinovic M, Labuda D, Richer C, et al. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 93: 1496-1501, 1999
  10. Balta G, Yuksek N, Ozyurek E, et al. Characterization of MTHFR, GSTM1, GSTT1, GSTP1, and CYP1A1 Genotypes in Childhood Acute Leukemia. Am J Hematol 73:154-160, 2003
  11. Barnette P, Scholl R, Blandford M, et al. High- Throughput Detection of Glutathione S-Transferase Polymorphic Alleles in a Pediatric Cancer Population. Cancer Epidemiol Biomarkers Prev 13: 304-313, 2004
  12. Davies SM, Robison LL, Buckley JD, et al. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 19:1279-87, 2001
  13. Ko Y, Koch B, Harth V, et al. Rapid analysis of GSTM1, GSTT1 and GSTP1 polymorphisms using real-time polymerase chain reaction. Pharmacogenetics 10: 1-4, 2000
  14. Ye Z, Song H. Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: A systematic review and meta-analysis. Eur J Cancer 41: 980-989,2005
  15. Ezer R, Alonso M, Pereira E, et al. Identification of glutathione S-